|
[1] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64 (1) :73-84.
|
|
[2]WONG RJ, MARIA A, RAMSEY C, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States[J].Gastroenterology, 2015, 148 (3) :547-555.
|
|
[3]National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association;Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol, 2018, 34 (5) :947-957. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :947-957.
|
|
[4]SAFIRI S, KHAZAEI S, MANSORI K, et al. Comments on increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:Systematic review and meta-analysis[J]. Hepatology, 2017, 65 (5) :1358-1359.
|
|
[5]BAFFY G. Origins of portal hypertension in nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2018, 63 (3) :1-14.
|
|
[6]LI B, SU Q. Relationship between advanced glycation endproducts and its receptor in nonalcoholic fatty liver diseases[J]. Int J Endocrinol Metab, 2017, 37 (3) :192-194. (in Chinese) 李博, 苏青.晚期糖基化终末产物及其受体与非酒精性脂肪性肝病的关系[J].国际内分泌代谢杂志, 2017, 37 (3) :192-194.
|
|
[7]LIU QB, LI HW. Advanced glycation end products and atherosclerosis[J]. Chin J Cardiovasc Med, 2018, 23 (1) :87-91. (in Chinese) 刘青波, 李虹伟.晚期糖基化终末产物与动脉粥样硬化[J].中国心血管杂志, 2018, 23 (1) :87-91.
|
|
[8]PAIZIS G, COOPER ME, SCHEMBRI JM, et al. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver[J]. Gastroenterology, 2002, 123 (5) :1667-1676.
|
|
[9]GARDEMANN A, PUSCHEL GP, JUNGERMANN K. Nervous control of liver metabolism and hemodynamics[M]//EJB Reviews. Springer Berlin Heidelberg, 1993:399-411.
|
|
[10]AMENTA F, CAVALLOTTI C, FERRANRE F, et al. Cholinergic nerves in the human liver[J]. Histochem J, 1981, 13 (3) :419-424.
|
|
[11]HYOGO H, YAMAGISHI S, IWAMOTO K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis[J]. J Gastroenterol Hepatol, 2007, 22 (7) :1112-1119.
|
|
[12]SAYEJ WN, KNIGHT LII PR, GUO WA, et al. Advanced glycation end products induce obesity and hepatosteatosis in CD-1 wildtype mice[J]. Biomed Res Int, 2016, 2016 (1) :7867852.
|
|
[13]YANG YL, ZHENG LY, GU WM, et al. Effect of total glucosides of paeony regulate HMGB1, RAGE pathway on nonalcoholic fatty liver disease in rats[J]. Chin J Clin Pharmacol Ther, 2017, 22 (6) :611-616. (in Chinese) 杨以琳, 郑琳颖, 古伟明, 等.白芍总苷对非酒精性脂肪性肝病大鼠HMGB1、RAGE通路的调控作用[J].中国临床药理学与治疗学, 2017, 22 (6) :611-616.
|
|
[14]PEREIRA ENGDS, SILVARES RR, FLORES EEI, et al. Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease[J]. PLo S One, 2017, 12 (6) :e0179654.
|
|
[15]HORIUCHI S. The liver is the main site for metabolism of circulating advanced glycation end products[J]. J Hepatol, 2002, 36 (1) :123-125.
|
|
[16]PALMA-DURAN SA, KONTOGIANNI MD, VLASSOPOULOS A, et al. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can discriminate non-alcoholic fatty liver disease in age-, sex-and BMI-matched normo-glycemic adults[J]. Metabolism, 2018, 83:120-127.
|
|
[17]McCUSKEY RS, ITO Y, ROBERTSON GR, et al. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice[J]. Hepatology, 2004, 40 (2) :386-393.
|
|
[18]FUJII M, SHIBAZAKI Y, WAKAMATSU K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma[J]. Med Mol Morphol, 2013, 46 (3) :141-152.
|
|
[19]LIEBIG M, HASSANZADA A, KMMERLING M, et al. Microcirculatory disturbances and cellular changes during progression of hepatic steatosis to liver tumors[J]. Exp Biol Med (Maywood) , 2018, 243 (1) :1-12.
|
|
[20]YU ZY. How to deal with fatty liver donor in liver transplantation[D]. Hangzhou:Zhejiang University, 2015. (in Chinese) 俞志勇.脂肪肝供肝肝移植的回顾性研究[D].杭州:浙江大学, 2015.
|
|
[21]MIYAO M, KOTANI H, ISHIDA T, et al. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression[J].Lab Invest, 2015, 95 (10) :1130-1144.
|
|
[22]MATSUKUMA S, TAKEO H, UTSUMI Y, et al. In hepatic venous outflow obstruction, alcoholic liver disease, and nonalcoholic fatty liver disease, centrilobular scars, CD34+vessels, and keratin 7+hepatocytes are in close proximity[J]. Virchows Archiv, 2017, 470 (4) :411-420.
|
|
[23]ZHAO YH, DUAN SP. Study on the relationship between blood lipid and hemorheology in patients with fatty liver[J]. Hebei Med, 2013, 19 (2) :304-306. (in Chinese) 赵艳会, 段淑平.脂肪肝患者血脂与血液流变学关系的研究[J].河北医学, 2013, 19 (2) :304-306.
|
|
[24]REEVES HL, FRIEDMAN SL. Activation of hepatic stellate cells—a key issue in liver fibrosis[J]. Front Biosci, 2002, 7 (1-3) :d808.
|
|
[25]POISSON J, LEMOINNE S, BOULANGER C, et al. Liver sinusoidal endothelial cells:Physiology and role in liver diseases[J]. J Hepatol, 2016, 66 (1) :212-227.
|
|
[26]DECARIS ML, LI KW, EMSON CL, et al. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood[J]. Hepatology, 2017, 65 (1) :78-88.
|
|
[27]NIU GH, GAO LW, QIAN JF, et al. Changes of platelet activation, hemorheology and nailfold microcirculation in patients with primary hepatocellular carcinoma[J]. Exp Lab Med, 2018, 36 (2) :234-236. (in Chinese) 牛国浩, 高立伟, 钱俊甫, 等.原发性肝癌患者血小板活化、血流变与甲襞微循环的变化研究[J].实验与检验医学, 2018, 36 (2) :234-236.
|
|
[28]WANG Q, YANG L. Research progress in quantitative evaluation by imaging biomarker of liver microenvironment[J]. J Med Imaging, 2017, 27 (2) :333-336. (in Chinese) 王倩, 杨立.影像生物学标记定量评价肝脏微环境的研究进展[J].医学影像学杂志, 2017, 27 (2) :333-336.
|
|
[29]STURESSON C, MILSTEIN DM, POST IC, et al. Laser speckle contrast imaging for assessment of liver microcirculation[J]. Microvasc Res, 2013, 87:34-40.
|
|
[30]NASR P, HILLIGES A, THORELIUS L, et al. Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease[J]. Scand J Gastroenterol, 2016, 51 (9) :1126-1132.
|
|
[31]ZHANG Y, JIA L. Double-blind study of aspirin in treating non-alcoholic fatty liver disease[J]. J Qiqihar Med Coll, 2015, 36 (31) :4687-4689. (in Chinese) 张影, 贾丽.阿司匹林治疗非酒精性脂肪肝的双盲研究[J].齐齐哈尔医学院学报, 2015, 36 (31) :4687-4689.
|
DownLoad: